51705-58-9

Usage

Uses

Used in Pharmaceutical and Medicinal Research:
[3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one is used as a compound in pharmaceutical and medicinal research for its potential biological activities. [3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one's unique structure and properties make it a promising candidate for the development of new drugs and therapies.
Used in Chemical Synthesis:
In the chemical industry, [3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one can be used as a key intermediate in the synthesis of more complex molecules, potentially leading to the development of novel pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Drug Delivery Systems:
Similar to other complex organic compounds, [3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one may be employed in the development of drug delivery systems. Its unique structure could be utilized to improve the delivery, bioavailability, and therapeutic outcomes of various drugs, particularly in the context of targeted drug delivery or controlled release applications.
Used in Analytical Chemistry:
[3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one's distinct chemical properties may also make it useful in analytical chemistry, where it could be employed as a reference material, a reagent, or a component in the development of new analytical methods or techniques.

Upstream product

• 40834-86-4 (3aR,4R,5R,6aS)-benzoic acid 2-oxo-4-[(1E)-3-oxo-oct-1-enyl]-hexahydro-cyclopenta[b]furan-5-yl ester 
• 215033-24-2 Benzoic acid (3aR,4R,5R,6aS)-4-{(E)-(R)-3-[((Z)-2-methyl-but-2-enyl)-diphenyl-silanyl]-oct-1-enyl}-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 215033-23-1 (Z)-(1S,5R,6R,7R,1'S)-7-Benzoyloxy-6-(1'-N-phenylcarbamoyloxyoct-2'-enyl)-2-oxabicyclo[3.3.0]octan-3-one 
• 215033-22-0 (Z)-(1S,5R,6R,7R,1'R)-7-Benzoyloxy-6-(1'-benzoyloxyoct-2'-enyl)-2-oxabicyclo[3.3.0]octan-3-one 
• 162992-65-6 (Z)-(1S,5R,6R,7R,1'S)-7-Benzoyloxy-6-(1'-hydroxyoct-2'-enyl)-2-oxabicyclo[3.3.0]octan-3-one 
• 162897-38-3 (Z)-(1S,5R,6R,7R,1'R)-7-Benzoyloxy-6-(1'-hydroxyoct-2'-enyl)-2-oxabicyclo[3.3.0]octan-3-one 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 36969-89-8 dimethyl 2-oxoheptylphosphonate 

Downstream Products

• 39182-59-7 (3aR,4R,5R,6aS)-5-hydroxy-4-((E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 851542-03-5 Benzoic acid (3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 69224-05-1 [3aR,4R(3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyoctyl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 95233-88-8 Benzoic acid (3aR,4R,5R,6aS)-4-((E)-(S)-3-acetoxy-oct-1-enyl)-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 733037-18-8 [3aR,4R(3S),5R,6aS]-5-benzoyloxy-4-(3-fluorooctyl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 38873-82-4 (15R)-PGE2 

Relevant academic research and scientific papers

Synthesis of 15R-PGD2: A potential DP2 receptor agonist

The first total synthesis of 15R-PGD2 3 was accomplished. The approach used in this report is also an efficient method to produce 15R-PGE 2. 15R-PGD2, a potential DP2 receptor agonist, could be an important novel tool for defining the role of this receptor in inflammatory diseases.

15-Fluoro prostaglandin FP agonists: A new class of topical ocular hypotensives

A novel series of 15-fluoro prostaglandins with phenoxy termination of the ω-chain was synthesized and evaluated for binding and functional activation of the prostaglandin FP receptor in vitro and for side effect potential and topical ocular hypotensive e

Stereocontrol in organic synthesis using silicon-containing compounds. A formal synthesis of prostaglandins controlling the stereochemistry at C-15 using a silyl-to-hydroxy conversion following a stereochemically convergent synthesis of an allylsilane

Hydrosilylation of isoprene with chloro(diphenyl)silane gave (Z)-chloro(2-methylbut-2-enyl)-diphenylsilane 7. The cuprate reagent derived from this chloride underwent conjugate addition to methyl cinnamate 11, 1,2-silylcupration with hex-1-yne 16 and allene 18, and allylic displacement reactions with 1-vinylcyclohexyl acetate 20 and (Z)-1-cyclopentyloct-2-en-1-yl acetate 22. The silyl group in each of the products was converted into a hydroxy, with the removal of the 2-methylbut-2-enyl group taking place under much milder acidic conditions than those needed to remove the phenyl group from the dimethyl(phenyl)silyl group, and making this group suitable for the conversion of an allylsilane into an allyl alcohol. A stereospecifically anti conjugate displacement of the allylic benzoate group in (Z)-(1S,5R,6R,7R,1′S)-7-benzoyloxy-6-(1′-benzoyloxyoct-2′- enyl)-2-oxabicyclo[3.3.0]octan-3-one 52, and a stereospecifically syn conjugate displacement of the carbamate group in (Z)-(1S,5R,6R,7R,1′R)-7-benzoyloxy-6-(1′-N-phenylcarbamoyloxyoct- 2′-enyl)-2-oxabicyclo[3.3.0]octan-3-one 51, gave stereo-convergently the same allylsilane (1′ E,2″Z)-(1S,5S,6R,7R,3′S)-7-benzoyloxy-6-[3′-(2″- methylbut-2″-enyl)-diphenylsilyloct-1′-enyl]-2-oxabicyclo[3.3.0] octan-3-one 53. Silyl-to-hydroxy conversion gave the allyl alcohol (E)-(1S,5S,6R,7R,3′S)-7-benzoyloxy-6-(3′-hydroxyoct-1′-enyl)- 2-oxabicyclo[3.3.0]octan-3-one 54, having the relative and absolute stereochemistry at C-15 of the prostaglandins.